Evid Invest
Holders — by stockHoldings — by fund

Eagle Health Investments LP

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001842545

$608.5M

disclosed book value

22

positions

12.1%

largest position share

Positions, as of 2026-09-30

top 23 of 22 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1ARGXARGENX SE76,593$73.4M12.1%
2GHGUARDANT HEALTH INC300,685$53.6M8.8%
3ICLRICON PUB LTD CO264,810$45.0M7.4%
4ISRGINTUITIVE SURGICAL INC108,546$44.1M7.3%
5UTHRUNITED THERAPEUTICS CORP DEL79,678$43.2M7.1%
6INSMINSMED INC358,702$40.9M6.7%
7PTGXPROTAGONIST THERAPEUTICS INC248,322$35.0M5.7%
8ROIVROIVANT SCIENCES LTD879,191$32.2M5.3%
9SRRKSCHOLAR ROCK HLDG CORP561,527$27.1M4.5%
10ASNDASCENDIS PHARMA A/S118,629$27.0M4.4%
11GHGUARDANT HEALTH INCPUT150,300$26.8M4.4%
12CMPSCOMPASS PATHWAYS PLC2.1M$25.6M4.2%
13RVMDREVOLUTION MEDICINES INC120,346$24.7M4.1%
14FTREFORTREA HLDGS INC1.2M$23.6M3.9%
15BSXBOSTON SCIENTIFIC CORP459,114$20.0M3.3%
16KYMRKYMERA THERAPEUTICS INC119,268$13.3M2.2%
17ALKSALKERMES PLC297,302$12.0M2%
18AXSMAXSOME THERAPEUTICS INC.65,051$12.0M2%
19DNTHDIANTHUS THERAPEUTICS INC131,344$11.6M1.9%
20REPLREPLIMUNE GROUP INC724,787$9.6M1.6%
21AVTXAVALO THERAPEUTICS INC235,093$3.6M0.6%
22SMMTSUMMIT THERAPEUTICS INC154,493$2.6M0.4%
23IMCRIMMUNOCORE HLDGS PLC46,300$1.4M0.2%

Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.